Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01799473
Other study ID # RIN-PH-404
Secondary ID
Status Completed
Phase N/A
First received February 12, 2013
Last updated March 20, 2015
Start date January 2013
Est. completion date December 2014

Study information

Verified date May 2014
Source United Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational [Patient Registry]

Clinical Trial Summary

This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso.

A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.


Recruitment information / eligibility

Status Completed
Enrollment 98
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Are newly prescribed Tyvaso for the treatment of PAH and plan to initiate therapy

- Are willing and able to be contacted by the patient call center.

Exclusion Criteria:

- Have previously received Tyvaso.

- Are currently enrolled in an interventional (non-FDA approved) PH clinical trial.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Puerto Rico CardioPulmonary Research Center Guaynabo
United States Queens Medical Center - Honolulu Aiea Hawaii
United States Presbyterian Heart Group Albuquerque New Mexico
United States Asheville Cardiology Associates Asheville North Carolina
United States Doctors Hospital of Augusta Augusta Georgia
United States Heart and Lung Associates, PC Bayside New York
United States Bay Area Cardiology Associates, PA Brandon Florida
United States New York Methodist Hospital Brooklyn New York
United States Florida Lung & Sleep Specialist Celebration Florida
United States The Rector and Visitors of the University of Virginia Charlottesville Virginia
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Children's Hospital Medical Center Cincinnati Ohio
United States The Cleveland Clinic Foundation Cleveland Ohio
United States Maury Regional Medical Center Columbia Tennessee
United States On Site Clinical Solutions Cumming Georgia
United States Midwest Pulmonary & Sleep Research Dayton Ohio
United States Duluth Biomedical Research Duluth Georgia
United States Sanford Heart Hospital Fargo North Dakota
United States Dor Heart and Vascular Clinic Gurnee Illinois
United States MedStar Health Institute Hyattsville Maryland
United States Clarian Health Methodist Hospital Indianapolis Indiana
United States The Regents of the University of California La Jolla California
United States Gwinnett Consultants in Cardiology Lawrenceville Georgia
United States UCLA Medical Center Los Angeles California
United States University of Wisconsin School of Medicine and Public Health Madison Wisconsin
United States Loyola University of Chicago Maywood Illinois
United States Southwest General Health Center Middleburg Heights Ohio
United States Madison Medical Affiliates Milwaukee Michigan
United States Medical College of Wisconsin Milwaukee Wisconsin
United States The Medical College of Wisconsin, Inc. Milwaukee Wisconsin
United States Sacred Heart Medical Group Miramar Beach Florida
United States Advocate Medical Group Oakbrook Illinois
United States INTEGRIS Baptist Medical Center, Inc Oklahoma City Oklahoma
United States Southern California Permanente Pasadena California
United States Singing River Health System Pascagoula Mississippi
United States Cardiology Consultants Pensacola Florida
United States Pensacola Lung Group Pensacola Florida
United States Sacred Heart Medical Group Pensacola Florida
United States Methodist Medical Center of Illinois Peoria Illinois
United States Pulmonary and Care Associates of Baltimore Pikesville Maryland
United States Carilion Medical Center Roanoke Virginia
United States Atlanta Cardiology Consultants Roswell Georgia
United States Pulmonary Consultants of San Antonio, PA San Antonio Texas
United States Central Coast Chest Consultants San Luis Obispo California
United States Pulmonary & Sleep Research Spokane Washington
United States Pacific Sleep Disorders Center Stockton California
United States Pediatrix Cardiology Associates Tampa Florida
United States AZ Perfection Clinical Union New Jersey
United States Prime Healthcare, PC West Hartford Connecticut
United States The Lankenau Institute for Medical Research Wynnewood Pennsylvania
United States WellSpan Health York Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
United Therapeutics

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Observe dose changes of Tyvaso over time 6 Months No
See also
  Status Clinical Trial Phase
Completed NCT04076241 - Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension N/A
Completed NCT05521113 - Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
Recruiting NCT04972656 - Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension N/A
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Recruiting NCT04266197 - Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study Phase 2
Active, not recruiting NCT06092424 - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA) N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Terminated NCT02060487 - Effects of Oral Sildenafil on Mortality in Adults With PAH Phase 4
Terminated NCT02253394 - The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Phase 4
Withdrawn NCT02958358 - FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan N/A
Terminated NCT01953965 - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. Phase 2
Unknown status NCT01712997 - Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients Phase 3
Withdrawn NCT01723371 - Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children Phase 1/Phase 2
Not yet recruiting NCT01649739 - Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Phase 4
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01165047 - Nitric Oxide, GeNO Nitrosyl Delivery System Phase 2
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1